×
About 175 results

ALLMedicine™ Adult Brain Tumor Center

Research & Reviews  62 results

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
https://clinicaltrials.gov/ct2/show/NCT05413304

Aug 12th, 2022 - Background Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2 year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the...

TRAF4 maintains deubiquitination of Caveolin-1 to drive glioblastoma stemness and Temoz...
https://doi.org/10.1158/0008-5472.CAN-21-3882
Cancer Research; Li Y, Wang T et. al.

Jul 28th, 2022 - Glioblastoma (GBM) is the most common type of primary adult brain tumor. Glioma stem cell (GSC) residence and Temozolomide (TMZ) resistance in GBM both contribute to poor patient outcome. TRAF4 is a scaffold protein with E3 ubiquitin ligase activi...

Using AI-Based Evolutionary Algorithms to Elucidate Adult Brain Tumor (Glioma) Etiology...
https://doi.org/10.3390/cimb44070206
Current Issues in Molecular Biology; McInerney CE, Lynn JA et. al.

Jul 26th, 2022 - Adult brain tumors (glioma) represent a cancer of unmet need where standard-of-care is non-curative; thus, new therapies are urgently needed. It is unclear whether isocitrate dehydrogenases (IDH1/2) when not mutated have any role in gliomagenesis ...

The future of cancer immunotherapy for brain tumors: a collaborative workshop.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125824
Journal of Translational Medicine; Brown CE, Bucktrout S et. al.

May 24th, 2022 - Harnessing the effector mechanisms of the immune system to combat brain tumors with antigen specificity and memory has been in research and clinical testing for many years. Government grant mechanisms and non-profit organizations have supported ma...

In Reply: Postacute Cognitive Rehabilitation for Adult Brain Tumor Patients.
https://doi.org/10.1227/neu.0000000000002016
Neurosurgery Weyer-Jamora C, Brie MS et. al.

Apr 27th, 2022 - In Reply: Postacute Cognitive Rehabilitation for Adult Brain Tumor Patients.|2022|Weyer-Jamora C,Brie MS,Luks TL,Smith EM,Hervey-Jumper SL,|

see more →

Clinicaltrials.gov  5 results

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
https://clinicaltrials.gov/ct2/show/NCT05413304

Aug 12th, 2022 - Background Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2 year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the...

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
https://clinicaltrials.gov/ct2/show/NCT01326104

Feb 7th, 2022 - Malignant brain tumors now represent the most frequent cause of cancer death in children. Despite aggressive and highly toxic multi-modality therapy including surgery, craniospinal radiation, and high-dose chemotherapy coupled with peripheral bloo...

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT02490930

Sep 13th, 2017 - Five evaluable patients with newly diagnosed high grade gliomas who will undergo standard concomitant radiation and temozolomide followed by adjuvant temozolomide will be accrued to this open-label, single arm, safety study. Oral fingolimod will b...

Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors
https://clinicaltrials.gov/ct2/show/NCT00594633

Jan 14th, 2016 - A significant proportion of brain tumor patients treated with radiation or chemotherapy who are in disease remission experience cognitive sequelae from their treatment. Cognitive dysfunction can be of sufficient severity to interfere with their ab...

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
https://clinicaltrials.gov/ct2/show/NCT01462695

Aug 27th, 2015 - PRIMARY OBJECTIVES: I. To estimate the objective response rate (partial response [PR] or complete response [CR] ≥ 8 weeks) to sunitinib in 2 strata (recurrent/progressive/refractory high-grade glioma vs ependymoma) of recurrent or progressive brai...

see more →

News  3 results

Enhancing Immune System May Boost Survival for Brain Cancer Patients
https://www.onclive.com/view/enhancing-immune-system-may-boost-survival-for-brain-cancer-patients

Oct 6th, 2021 - Jian Li Campian, MD, PhD Medical Oncologist Assistant Professor of Medicine Siteman Cancer Center Washington University School of Medicine St. Louis, MO The concept that the immune system plays a pivotal role in the prevention and co...

Alzheimer’s drug improves cognitive function after RT for brain tumors
https://www.mdedge.com/internalmedicine/article/98906/alzheimers-cognition/alzheimers-drug-improves-cognitive-function
Jennifer Kelly Shepphird

Apr 20th, 2015 - Adult brain tumor survivors taking donepezil, a drug approved for the treatment of Alzheimer’s disease, showed significant improvements in the cognitive functions of memory, motor speed, and dexterity, compared with those taking a placebo. However.

Gene and Pathway Alterations Identified in Both Glioblastoma Multiforme and Pancreatic Cancer
https://www.medscape.com/viewarticle/580110

Sep 5th, 2008 - September 5, 2008 — A trio of genomic studies published yesterday in Nature and Science point to specific genes and signaling pathways that characterize 2 human cancers. The results suggest a potential for targeted therapies in glioblastoma multif...

see more →